Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2914-2923

  Boruchov, Adam M ^a,b   Heller, Glenn ^a   Veri, Maria Concetta ^c   Bonvini, Ezio ^c   Ravetch, Jeffrey V ^d   Young, James W ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Analytical Sciences   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD32 ANTIGEN; CD32A ANTIGEN; CD32B ANTIGEN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MONOMER; PROTEIN P70; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL MATURATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GENE TARGETING; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE COMPLEX DISEASE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MONOCYTE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOGLOBULIN G; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-12; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MONOCYTES; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 26444577543     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24772     Document Type: Article

References (49)

1. Waldmann, T.A. 2003. Immunotherapy: past, present and future. Nat. Med. 9:269-277.
2. Edwards, J.C.W., et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350:2572-2581.
3. Ravetch, J.V., and Holland, S. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
4. Fanger, N.A., Wardwell, K., Shen, L., Tedder, T.F., and Guyre, P.M. 1996. Type 1 [CD64] and type 11 [CD32] Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 157:541-548.
5. Regnault, A., et al. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380.
6. Dhodapkar, K.M., Krasovsky, J., Williamson, B., and Dhodapkar, M.V. 2002. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195:125-133.
7. Kalergis, A.M., and Ravetch, J.V. 2002. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195:1653-1659.
8. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-446.
9. Mellman, I., and Steinman, R.M. 2001. Dendritic cells: specialized and regulated antigen processing machines [review]. Cell. 106:255-258.
10. Van Sorge, N.M., Van der Pol, W.L., and Van de Winkel, J.G. 2003. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy [review]. Tissue Antigens. 61:189-202.
11. Schlossman, S.F., et al. 1995. Leucocyte typing V: white cell differentiation antigens. Oxford University Press. Oxford, United Kingdom/New York, New York, USA. 2044 pp.
12. Gamberale, R., et al. 2003. Expression of Fcgamma receptors type II (FcgammaRII) in chronic lymphocytic leukemia B cells. Blood. 102:2698-2699.
13. Maresco, D.L., Osborne, J.M., Cooney, D., Coggeshall, K.M., and Anderson, C.L. 1999. The SH2-containing 5′-inositol phosphatase (SHIP) is tyrosine phosphorylated after Fcgamma receptor clustering in monocytes. J. Immunol. 162:6458-6465.
14. Parren, P.W., et al. 1992. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90:1537-1546.
15. Denomme, G.A., et al. 1997. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia. J. Lab. Clin. Med. 130:278-284.
16. Vely, F., et al. 1997. A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. Hybridoma. 16:519-528.
17. Warmerdam, P., van de Winkel, J., Gosselin, E., and Capel, P. 1990. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J. Exp. Med. 172:19-25.
18. Looney, R.J., Anderson, C.L., Ryan, D.H., and Rosenfeld, S.I. 1988. Structural polymorphism of the human platelet Fc gamma receptor. J. Immunol. 141:2680-2683.
19. Siegal, F.P., et al. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science. 284:1835-1837.
20. Dzionek, A., et al. 2000. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165:6037-6046.
21. Passlick, B., Flieger, D., and Ziegler-Heitbrock, H.W. 1989. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 74:2527-2534.
22. Geissmann, F., Jung, S., and Littman, D.R. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 19:71-82.
23. Jonuleit, H., et al. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135-3142.
24. Grouard, G., et al. 1997. The enigmatic plasmacytoid T cells develop into dendritic cells with IL-3 and CD40-ligand. J. Exp. Med. 185:1101-1111.
25. Banki, Z., et al. 2003. Cross-linking of CD32 induces maturation of human monocyte-derived dendritic cells via NF-kappaB signaling pathway. J. Immunol. 170:3963-3970.
26. Zhou, L.-J., and Tedder, T.F. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154:3821-3835.
27. Weng, W.K., and Levy, R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947.
28. Sallusto, F., and Lanzavecchia, A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109-1118.
29. Ravetch, J.V., and Lanier, L.L. 2000. Immune inhibitory receptors. Science. 290:84-89.
30. Bolland, S., and Ravetch, J.V. 2000. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 13:277-285.
31. Clatworthy, M.R., and Smith, K.G. 2004. FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J. Exp. Med. 199:717-723.
32. Uchida, J., et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199:1659-1669.
33. McGaha, T.L., Sotrentino, B., and Ravetch, J.V. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 307:590-593.
34. Samuelsson, A., Towers, T.L., and Ravetch, J.V. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:484-486.
35. Charles, P., et al. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163:1521-1528.
36. Rose, A.L., Smith, B.E., and Maloney, D.G. 2002. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 100:1765-1773.
37. Dyall, R., Vasovic, L.V., Clynes, R.A., and Nikolic-Zugic, J. 1999. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29:30-37.
38. Amigorena, S. 2002. Fc gamma receptors and cross-presentation in dendritic cells. J. Exp. Med. 195:F1-F3.
39. Munz, C., et al. 2005. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 105:266-273.
40. Dubois, B., et al. 1997. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J. Exp. Med. 185:941-951.
41. Dhodapkar, K.M., et al. 2005. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. U. S. A. 102:2910-2915.
42. Berger, S., Chandra, R., Ballo, H., Hildenbrand, R., and Stutte, H.J. 1997. Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur. J. Immunol. 27:2994-3000.
43. Radstake, T.R., et al. 2004. High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. Ann. Rheum. Dis. 63:696-702.
44. Amigorena, S., et al. 1992. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science. 256:1808-1812.
45. Carcao, M.D., et al. 2003. Fcgamma receptor IIa and IlIa polymorphisms in childhood immune thrombocytopenic purpura. Br. J. Haematol. 120:135-141.
46. Tax, W.J., Willems, H.W., Reekers, P.P., Capel, P.J., and Koene, R.A. 1983. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature. 304:445-447.
47. Armour, K.L., van de Winkel, J.G., Williamson, L.M., and Clark, M.R. 2003. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol. Immunol. 40:585-593.
48. Thurner, B., et al. 1999. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application [review]. J. Immunol. Methods. 223:1-15.
49. de Saint-Vis, B., et al. 1998. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 9:325-336.